More than ten biosimilars to Humira^® were launched in 2023, introducing price competitiveness for one of the most utilized drugs on the market....

Our recent August Pharmacy and Therapeutics (P&T) Committee meeting reviewed the release of various Humira® biosimilars. Staying true to our...

In an ever-changing legislative landscape, we want to help our clients and partners stay informed of the latest happenings and how proposed policies...

This summer has seen a continuation of the long-awaited market entry of Humira^® (adalimumab) biosimilars. As of July 1, nine additional biosimilars...

We are pleased to share our 2022 Drug Trend Report with you. This year's report highlights our success in managing pharmacy benefit costs for our...

The market entry of biosimilars to Humira^® (adalimumab) is long-awaited. These products have the potential to improve affordability in the near- and...

As we enter 2023, David Fields is sharing his top forecasts and takeaways for plan sponsors and the PBM industry.

Navitus’ Vice President of Government Relations, Robyn Crosson, shares her insight into the Inflation Reduction Act and how it will impact our...

This week we provide an overview of our 2021 drug trend and client savings with insights for 2022 and beyond.

Carrie Aiken, Navitus’ Vice President of Corporate Compliance and Chief Compliance Officer, shares her perspective on how PBMs can help plan sponsors...

Sharon Faust, PharmD, Vice President of Specialty Pharmacy for Lumicera shares a few key initiatives that will continue to create an impact for...

As a member, plan sponsor or consultant, do you understand what the new federal guidance on free at-home COVID-19 tests means to you? As part of...